Teladoc Health TDOC Incentive stock program, shares reserved for future grants (in shares)

Incentive stock program, shares reserved for future grants (in shares) at other companies

CareDxCDNA

——

Revenue$613.8M-2.5%

Gross profit$416.3M-3.8%

Operating income-$61.8M+48.8%

Net income-$63.8M+31.4%

EPS (diluted)-$0.36+32.1%

Cash & equivalents$750.7M-37.1%

Total debt$42.2M-92.9%

Total equity$1.3B-6.4%

Total assets$2.8B-18.5%

Operating cash flow$9.5M-40.2%

CapEx$1.7M-39.1%

Free cash flow$7.9M-40.5%

Market cap$1.41B-29.7%

Enterprise value$701.31M-66.3%

P/S0.6×-0.2×

Gross margin69.3%-1.2pp

Operating margin-8.1%-3.6pp

Net margin-6.8%-3.1pp

FCF margin11.1%-0.2pp

Return on equity-12.4%-5.4pp

Debt / equity0×-0.4×

Current ratio2.8×+1.1×

Reported directly by Teladoc Health in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.

The official record: Teladoc Health’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Teladoc Health's incentive stock program, shares reserved for future grants (in shares)?: Teladoc Health (TDOC) reported incentive stock program, shares reserved for future grants (in shares) of $7.1M in Q1 2026.
How has Teladoc Health's incentive stock program, shares reserved for future grants (in shares) changed year-over-year?: Teladoc Health's incentive stock program, shares reserved for future grants (in shares) decreased by 11.3% year-over-year, from $8M to $7.1M.